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Abstract: Multiple myeloma (MM), a clonal plasma cell disorder, disrupts the bones’ hematopoiesis
and microenvironment homeostasis and ability to mediate an immune response against malignant
clones. Despite prominent survival improvement with newer treatment modalities since the 2000s,
MM is still considered a non-curable disease. Patients experience disease recurrence episodes with
clonal evolution, and with each relapse disease comes back with a more aggressive phenotype.
Bruton’s Tyrosine Kinase (BTK) has been a major target for B cell clonal disorders and its role in
clonal plasma cell disorders is under active investigation. BTK is a cytosolic kinase which plays a
major role in the immune system and its related malignancies. The BTK pathway has been shown to
provide survival for malignant clone and multiple myeloma stem cells (MMSCs). BTK also regulates
the malignant clones’ interaction with the bone marrow microenvironment. Hence, BTK inhibition
is a promising therapeutic strategy for MM patients. In this review, the role of BTK and its signal
transduction pathways are outlined in the context of MM.
Keywords: multiple myeloma; microenvironment; Bruton’s Tyrosine Kinase (BTK) inhibitors; resis-
tance; drug development
1. Introduction
Multiple myeloma (MM) is clonal proliferation of malignant plasma cells in the bone
marrow microenvironment (BMM), and it accounts for approximately 1% of all neoplastic
diseases and 15% of all blood cancers, making it the second most common hematological
malignancy after lymphoma [1,2]. There have been substantial changes in the treatment of
MM during the last 20 years and those changes increased the five-year survival rates for
patients from 12% to 54% (SEER data. Cancer Statistic Review 1975–2016. National Cancer
Institute 2019).
Plasma cells reside in the bone marrow where they normally comprise 0.25% of
mononuclear cells, but in MM, monoclonal plasma cells accumulate and alter the BMM.
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This accumulation leads to disruptions in bone remodeling compartments, increased lytic
activity, impaired cellular immunity and angiogenesis [3]. Historically, due to the rarity of
plasma cells, their production and biology have been poorly understood. However, recent
advances in the field have led to the identification of numerous potential therapeutic targets
for MM [3]. These treatment modalities include combinations of proteasome inhibitors (PI),
immunomodulatory drugs (IMIDs), alkylating agents, monoclonal antibodies (i.e., anti-
CD38 and anti-SLAMF7), histone deacetylase inhibitors, B cell maturation antigen (BCMA)
targeted drug-antibody conjugate, autologous stem cell transplantation (ASCT) and most
recently BCMA targeting CAR-T cells. In spite of recent progress in the development of
new and increasingly effective agents, MM remains incurable, mostly due to the evolution
of drug-resistant clones [4]. Drug resistance of MM has been shown to be mediated through
several mechanisms including loss of CD38 expression, BCMA expression, proteasome
subunit β type 5 (PSMB5) point mutation or overexpression, and Cereblon (CRNB) down
regulation, all of which help to produce MM stem-like cells (MMSCs). Therefore, successful
alternative treatments of the stem-cell-like phenotypes is a critical focus in MM research
moving forward [5,6].
Examining the molecular mechanisms of how the aggressive and drug resistant
myeloma cells interact with the supporting stroma can allow for better patient tailored
clinical management through targeting and disrupting the tumors’ protective niche [6].
2. Bruton’s Tyrosine Kinase, Structure and Regulation
Protein kinases (PTKs) act like a person flipping a molecular switch to control whether
proteins are turned on or off. Kinases accomplish this by facilitating the transfer of a
phosphate group from ATP to either a serine, threonine or tyrosine residue of their target
protein [7,8]. BTK is one of the five Tec family kinases, a group of cytosolic kinases that
phosphorylate tyrosine residues. The other four Tec family kinases include: Txk/Rlk,
Itk/Emt/Tsk, Bmx and Tec, the enzyme which the family was named after [9]. The Tec
family of kinases are one branch of the Src module kinases that mediate an array of cellular
signaling processes. The other Src module kinases include ABL, CSK, FRK and BRK
families [8].
Structurally, the SRC root module that the Tec family of kinases stem from consists
of a single polypeptide chain comprising an SH3 and an SH2 domain. The SH2 domain
is connected by an SH2-kinase linker to the kinase domain (AKA; SH1 domain), which is
ultimately responsible for catalytic activity [8]. In BTK’s inactive state, the SH2 and SH3
domains impinge upon the kinase domain, thereby stabilizing inactivity and providing
allosteric control over the catalytic site. The hallmark feature of the Tec family kinases
that differentiates them from their relative kinases is the presence of the amino terminal
Pleckstrin Homology (PH) domain that also confers allosteric control by further stabilizing
the inactive conformation [9]. Following the amino PH domain is a proline-rich Tec
homology (TH) domain, followed by the Src domains SH3, SH2 and the carbonyl SH1
domain [7] (Figure 1).
Genetically, BTK has been shown in humans to be on the long q arm of the X chro-
mosome at location Xq22.3-q22. The gene encompasses 37.5 kb, contains 19 exons and
is expressed in all hematopoietic cells with the exception of T cells and possibly plasma
cells [10]. Loss of the X chromosome has been reported in MM; however, these cases
are leading to monosomy in females, therefore complete loss of BTK coding does not
occur. There is little data supporting amplification of the BTK coding portions of the X
chromosome in MM.
BTK is primarily cytosolic but can be recruited to the cell membrane due to interac-
tions with its PH domain. The PH domain confers the ability to bind to phosphoinositides,
thereby merging the tyrosine kinase and the phospholipid signaling systems [9,11]. BTK
activation has been shown to be directly linked to its initial membrane recruitment and
subsequent phosphorylation. Following its recruitment to the membrane, BTK activation
occurs in two steps. Step one is the trans-phosphorylation of BTK on tyrosine residue at
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position 551 (Y551) in the kinase domain by either Lyn, SYK or other Src family kinases [12].
This first step is thought to be responsible for the enzymes’ catalytic ability and conse-
quently results in the second step, autophosphorylation of tyrosine at position 223 (Y223)
in the SH3 domain [13]. The Y223 position of the SH3 domain is highly conserved among
signaling proteins and is thought to lie in the surface of the ligand-binding groove, which
implies that this autophosphorylation may play a role in protein-protein interactions as
well as stabilizing the active form, although the extent of these interactions is not fully
understood [7,13].




Figure 1. Structure of BTK. The crystal structure of BTK kinase domain (colored magenta; PDB: 3GEN) and SH2 domain 
(colored red; PDB: 2GE9). Bar Diagram representing the domain organization of the BTK protein. 
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BTK a tivation can occur through ot er Src kinas s bu is primarily regulated by its
transient recrui ment to the cell m mbrane through the canoni al PH-TH module with
phosphatidylinositol (3,4,5)-trisphospha e (PIP3) membrane ipids and ubsequent pho -
phorylation. Little is known about the st uctural mechanism of this m mbrane inter ct on.
However, recent si u ations sugg st that PIP3 acts as a regulator of BTK activity as it con-
trols PH-TH Saraste di erization within the cell membrane, which may be an important
step in enzymatic activation [13–15]. BTK catalytic activity and tyrosine phosphorylation
increases n response to cross linking or stimulation of t e sIGM complex, the IL-5 or IL-6
receptors of B cells and the IgE receptor of mast cells, all of which are over expre se in
MM patients. BTK activation the triggers activation f rotein kinase B (AKT), phospholi-
pase c (PLC) and calcium mobilization, leading to increased downstream effects includi g
proliferation, differentiation and cell survival. Thus, chronic activation of BTK through the
tyrosine kinase or phospholipid signaling systems can be a key driver in several neoplastic
malignancies and a valuable therapeutic target in many more [16].
3. BTK as a Potential Target in Malignancies
The phosphorylation of proteins is by far the most common form of reversible post-
translational modifications that modulate the activity of biochemical signaling pathways
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in humans [17]. The PTKs alter specific substrate activity and/or interactions with other
proteins and are a fundamental method of controlling the cell cycle. PTK inhibition (PTKi)
has proven to be an effective and accessible way to favorably alter the cellular signaling
underlying hundreds of pathologies, including cancer [7,17]. This is largely due to the
abnormal activation and dysregulation of these kinase mediated pathways which act as
driving forces in many malignancies. In cancer cells, this abnormal activation can lead to
increases in proliferation, stemness, survival, migration, motility and metabolism, all of
which are associated with less favorable outcomes in patients [7].
The BTK pathway is universal in blood cells, as its signaling molecules are expressed
in all hematopoietic lineages [18]. BTK in particular plays a crucial role in the development
of peripheral B-cells as well as the survival of leukemic cells and their interaction with
the BMM [7,19]. BTK is located in the cytoplasm of B-cells and is required for proper
B-lymphocyte development, differentiation and signaling [11]. When the gene encoding
BTK is mutated, a condition called X chromosome-linked agammaglobulinemia (XLA)
results. This condition is characterized by minimal B cell populations and ultimately
results from altered B cell receptor (BCR) signaling and high rates of apoptosis. Clinically,
patients with XLA exhibit impaired immune function, reductions in all classes of serum
immunoglobulins, markedly reduced B cell lymphocytes populations, severe neutropenia,
and an inability to make antibodies in response to vaccines and repetitive bacterial infec-
tions that onset several months after infancy [20]. Due to this relation, the kinase itself is
named after the Pediatrician Ogden Bruton, who reported the first case of XLA in 1952
(Figure 2) [21].
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BTK is essential in the B-cell receptor signaling of peripheral B cells, as it inhibits 
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Figure 2. A Timeline of BTK and its inhibitor. BTK has made re arkable r r i i it tr t e t in a
variety of B cell related malignancies and even more clinical trials are underway, including some in .
BTK plays an important role in vari l s si es R
signaling, che okine receptor 4 (CXCR4) signaling, toll-like receptor (TLR)
Int. J. Mol. Sci. 2021, 22, 5707 5 of 18
signaling and Fc receptor signaling. Many of these signaling pathways result in common
downstream effects due to the activation of BTK. For instance, BCR and CXCR4 activation
of BTK have both been implicated to be important in controlling the adhesion of vascular
cell adhesion proteins (VCAM) [7,22]. A comprehensive outline of how BTK interacts in
each of these pathways and the implications it has in neoplasm is provided below.
B Cell Receptor Signaling: Due to BTK’s causal role in the B cell disorder XLA, the most
thoroughly understood pathway which it mediates is B Cell Receptor (BCR) signaling [7]. In
the germinal center, BCR, TLR and CD40 signaling are recognized as playing a fundamental
role in the differentiation of B cells to plasma cells. After activation of B cells through BCR,
TLR and/or CD40, upregulation of interferon regulatory factor 4 (IRF4) expression and
downregulation of B-Cell Lymphoma 6 (BCL-6) expression occurs in addition to a loss
of PR/Set Domain 1 (PRDM1) repression, resulting in down regulation of Paired Box 5
(PAX5) gene and upregulation of X-Box Binding Protein 1 (XBP1) and ultimately resulting
in a loss of the B cell gene activation and phenotype. Furthermore, in the centrocyte region,
stimulation of Interleukin 10, 21 or 6 (IL-10, IL-21 or IL-6) results in signal transducer and
activator of transcription 3 (STAT3) activation, yielding PRDM1 overexpression and hence
the gain of the plasma cell phenotype (Figure 3) [3].
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BTK is essential in the B-cell receptor signaling of peripheral B cells, as it inhibits
apoptotic signals and controls proliferation, differentiation, and adhesion. In the absence
of BTK, peripheral B cells have a high rate of apoptosis, corresponding to BTK’s role in
induction of anti-apoptotic protein Bcl-xL. Following BCR antigen engagement, either
SYK or Lyn are required to initiate the formation of a signalosome at the cell me brane,
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allowing for efficient signal transduction. The signalosome also contains; Cbl-interacting
protein of 85 kDa (CIN85), the SH2 containing leukocyte protein of 65 kDa (SLP65), and
B cell linker (Blnk) [23]. SLP65 acts as a scaffold protein orientating several signaling
proteins including SYK, BTK and phospholipase Cγ2 (PLCγ2). Through this complex,
SYK phosphorylates BTK, thereby allowing BTK to activate PLCγ2 and initiate a cascade
by activating four separate families of different non-receptor protein kinases, resulting
in key cell proliferation and survival signaling events. These activated kinases include
PLCγ2, mitogen-activated protein kinase (MAPK), protein kinase B (AKT) and components
of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway
(Figure 3). These kinases activate several notable downstream targets with direct impacts
on increasing cell survival rate, drug resistance, stemness and ultimately relapse in the case
of MM.
After phosphorylation of PLCγ2 by BTK, PLCγ2 can hydrolyze phosphatidylinositol
4,5-bisphosphate (PIP2) into inositol triphosphate (IP3) and diacylglycerol (DAG). IP3
modulates intracellular calcium levels and thereby can activate nuclear factor of activated
T-cells (NFAT) transcription through calcineurin and calmodulin. DAG mediates activation
of PKCβ, which can induce activation of several members of the MAPK family, including
extracellularly regulated kinases 1 and 2 (ERK1/2), c-jun N-terminal kinase (JNK), p38 and
NF-κB (Figure 3).
On the other hand, AKT activation by BTK leads to downstream activation of prolifer-
ation and pro-survival protein pathways such as mammalian target of rapamycin (mTOR),
NFAT, Forkhead Box O proteins (FOXOs) and NF-κB.
Besides the kinases it activates, the BCR has also been shown to play a role in con-
trolling integrin α4β1 (VLA-4)-mediated adhesion of B cells to VCAM and fibronectin,
alluding to the role BTK can play in the metastasis of B cell malignancies and their tumor-
stroma interactions. BTK directly interacts with Wiskott-Aldrich syndrome protein (WASP),
leading to its activation which induces RAC-dependent actin filament rearrangements. This
has been shown to be dependent on BTK, PLCγ2 and PKCβ but not ERK1 or ERK2 [7,24].
Chemokine Receptor Signaling: Chemokines are secreted proteins that function as a
leukocyte-specific chemoattractant. CXCR4 is one of the many chemokine receptors, and is
a G coupled protein receptor expressed in many hemopoietic and non-hemopoietic cell
types. CXCR4 has been studied intensively; it binds stromal cell-derived factor 12 (CXCL12),
CD4 and CD74, it is overexpressed in 23 human cancers and plays important roles in
immune response, hematopoiesis and pro-tumorigenicity.
When CXCR4 binds its endogenous ligand, CXCL12, which is highly expressed
in the bone marrow, the trimeric G-protein subunits of CXCR4 dissociate and activate
several pathways involved in chemotaxis, intracellular calcium flux, cell adhesion, survival,
proliferation and gene activation. Therefore, CXCR4 activation in neoplasm is linked to
increased proliferation, metastasis, angiogenesis, drug resistance and ultimately relapse.
Accordingly, blocking the receptor has been shown to have therapeutic effects in MM
including the disruption of tumor-stroma interactions, reduced proliferation, sensitization
to cytotoxic agents, impaired homing and inhibited metastasis [25,26]. Several studies have
shown that in MM, CXCR4 is aberrantly activated and associated with the progression,
spread and relapse of the cancer. CXCR4 activation in MM is shown to be induced by
several factors including hypoxia, TNF-α, TNF-β and VEGF.
BTK is an important signal transductor in CXCR4-CXCL12 signaling as BTK inhibition
has been shown to deregulate CXCR4 expression and signaling [27]. After CXCL12 has
bound to CXCR4, the Gα and Gβ subunits activate PI3K. PI3K activation then interacts
with the PH domain of BTK, recruiting it to the cell membrane, allowing for BTK activation
and leading to PLCγ2, AKT, MAPK and NF-κB pathway activation. In addition to PI3K
activation of BTK, the Gα and Gβ subunits can both directly bind to BTK at the PH and TH
domains and the Gα subunit can activate BTK directly. When BTK is inhibited, it has been
shown to inhibit CXCL12 and CXCL13 induced phosphorylation of PLCγ2, ERK1, ERK2,
JNK and AKT proteins, proving BTK’s role in this major pathway (see Figure 3) [7,28].
Int. J. Mol. Sci. 2021, 22, 5707 7 of 18
Toll-Like Receptor Signaling: Toll–like-receptors (TLRs) are membrane bound re-
ceptors that mediate the innate immune system and are activated by binding ligands
produced by various pathogens [29]. Toll-like receptor (TLR) signaling has synergis-
tic and crosstalk effects with CXCR4 and BCR signaling, all of which are mediated by
BTK [30]. In TLR signaling, BTK is required for the downstream activation of NF-κB and
interferon regulatory factor-dependent transcription of inflammatory cytokine and inter-
ferons due to BTK’s interaction with various proteins, including Myeloid differentiation
primary response 88 (MYD88), Toll/Interleukin-1 receptor (TIR), Interleukin-1 receptor-
associated kinase 1 (IRAK1) and Toll/Interleukin1 receptor domain-containing adaptor
protein (TIRAP)/Myelin and lymphocyte protein (MAL) [7,28]. Following TLR binding to
lipopolysaccharides, most TLRs bind MYD88, initiating a signaling cascade activating TIR,
IRAK1 and TIRAP/MAL, leading to BTK activation. BTK’s interplay between TLR and
BCR signaling may therefore interconnect the two pathways (Figure 3) [31].
Fc Receptor Signaling: Fc receptors are shown to be expressed broadly in hematopoi-
etic lineages and can mediate phagocytosis, release of inflammatory mediators, antibody
dependent cell-mediated cytotoxicity and humoral tolerance in different cell types. In
plasma cells, FCγRIIB plays an important role in regulating survival and homeostasis [32].
Activation of FcγRI receptors results in the activation of BTK, STK and PI3K. On the
other hand, FCγRIIB receptor activation inhibits BTK through the recruitment of phos-
phatases. Inhibiting Fc receptor pathways can lead to a reduction in the supportive role of
macrophage cells and thus a reduction in vascularization.
BTK Inhibition in MM cells leads to decreases in several key effects of BCR, CXCR,
TLR and Fc receptor activation. By blocking BTK and inhibiting all four of these pathways,
MM cells causes decreased levels of phosphorylated ERK, AKT, and PLCγ2, yielding
decreases in expression of many genes related to oncogenicity including mTORC1, NFκB,
ELK1/2, NFAT, MYK and more (Figure 3).
As previously touched upon, BTK activation through one pathway has important
interactions and crosstalk with other pathway molecules. For instance, BTK is activated by
the BCR pathway and then can indirectly affect components of the TLR and chemokine
signaling pathway, thereby adding complexity to its study [28]. Due to BTK’s role in
activating numerous malignancy related pathways such as NFκB, AKT, mTOR, NFAT
and more, the compound appears as an extremely attractive target for a number of blood
related malignancies. BTK is particularly suitable as a targeted therapy in MM due to
its critical role in the development of B cells within the bone marrow and its effects on
numerous components in the BMM (Figure 2).
4. Role of BTK in Bone Marrow Microenvironment
MM as a cancer ultimately resides within the BM, as this is the home of plasma cells.
Over the past two decades it has become increasingly evident that alterations to the BMM
and the signals arising from it have crucial effects in the progression of MM and several
other B cell malignancies [3,33,34]. The treatment of MM is particularly difficult due to the
supportive role which the BMM plays. The cellular compartment of the microenvironment
consists of stromal cells, osteoblasts, osteoclasts, osteal-macrophages, endothelial cells, and
immune cells. It has been shown that the BMM can aid in the differentiation, migration,
proliferation, survival, and drug resistance of cancerous plasma cells [35]. The BMM
produces its drug protective niche by releasing adhesion molecules and cytokines that
allow hardy MM cells and stem cells to survive cytotoxic chemotherapies. Furthermore,
when MM plasma cells and BM stromal cells (BMSCs) interact, it prompts the stroma to
ramp up cytokine production further and activates several onco-related pathways including
JAK/STAT, Ras/Raf/MEK/MAPK, PI3K/AKT and NF-κB (Figure 3) [36]. BTK has several
important roles in these BMM pathways, which ultimately contribute to a substantial bulk
of the BTK inhibitor’s therapeutic potential.
Accumulation of plasma cells in the BMM, as occurs in MM, interferes with osteoblasts
activity, and disrupts the normal balance of osteoblast bone formation and osteoclast bone
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resorption. These interactions in the bone are referred to as bone remodeling compartments
(BRCs). When MM disrupts BRCs, osteoblast count and overall function decreases, causing
a net-loss of bone and the hallmark bone lesions found in patients. This effect is exacerbated
by a type of positive feedback loop, since osteoclasts stimulate myeloma cell survival and
proliferation through direct binding interactions and myeloma cells increase the number
and activity of osteoclasts. Osteoclast activity and bone resorption both release growth
factors, such as IGF-1, which activate the PI3K pathway phosphorylating AKT protein
independent of the JAK/STAT pathway. IGF-1 can also induce MAPK phosphorylation.
BTK has been shown to be an important part of PI3K signaling and its inhibition reduces
PI3K signaling output, blunting some of these IGF-1 mediated effects. This is because
BTK and PI3K interact in the same pathways and are both required to elicit full AKT
activation [3,37]. Furthermore, BTK is selectively expressed in osteoclasts, leading it to
have a direct role in osteoclast function and bone resorption. BTK has also been shown
to mediate the migration of osteoclast precursors towards stromal cell-derived factor-1
(SDF-1) and their differentiation to osteoclasts [38].
IL-6 is overproduced mainly by the monocytes, myeloid cells, and stromal cells of
BMM in patients with MM. This overproduction is triggered by the IL-1 produced by
monocytes and myeloma cells, as only a small amount of IL-1 is required to promote the
production of large amounts of IL-6. Patients with high serum levels of IL-6 are associated
with poor prognosis [3]. In a study of MM cells in co-culture with BMSCs or osteoclasts,
BTK inhibition has been shown to be most potent against IL-6 or stroma dependent MM
cells, suggesting that cytotoxic effects against MM cells in these treatments was by proxy of
altering the BMM. The cytotoxic effects mediated through the BMM were accompanied
by the suppressing of multiple chemokines and cytokines, including IL-6, SDF-1, activin
A, IL-8, BAFF, M-CSDF and MIP1B [39]. This may be attributed to BTK’s role in the
NLRP3 inflammasome, which is known to be a key player in the activation of bioactive
IL-1β. BTK was shown to be a direct regulator of said NRLP3 inflammasome via direct
interactions. Without active BTK, the NRLP3 was unable to induce IL-1β secretion [40].
BTK has also been shown to have a strong effect on myeloid-derived suppressor cells
(MDSCs) that inhabit the BMM, inhibiting T cell function and contributing to tumor
progression. MDSCs are known to reduce the efficacy of immune based treatments and
BTK inhibition has been shown to be able to inhibit MDSC generation, migration, and
production of immunosuppressive chemicals such as nitric oxide (NO) and indolamine
2,3-dioxygenase [41].
BTK has also been implicated in playing a role in macrophages that reside and migrate
to the BM. Emerging evidence shows that macrophages play an important role in primary
tumors that metastasize to the skeleton. BTK inhibition in macrophages has been shown
to suppress their production of CXCL12, CXCL13, CCL19 and VEGF, thereby negatively
affecting the adhesion, invasion, and migration of lymphoid cells, including mechanisms
not directly mediated through BTK [30]. The role in which macrophages play in the BMM
in MM remains to be elucidated further but macrophages treated with BTK inhibitors have
been shown to reduce their secretion of MM supportive factors and expression of NF-κB,
STAT3 and AP-1 [41].
Besides its expression in the BMM, studies examining gene expression profiling and
immunoblotting have demonstrated significant expression of BTK in more than 85% of
MM patients. Studies in which BTK was blocked using Ibrutinib in myeloma cells showed
inhibition of tumor survival and proliferation through the NFκB, STAT3, ERK1/2 and
AKT signaling pathways [39]. The effect that BTK inhibitors have on chemokine receptors
and fibronectin adhesion have been shown to have effects in myeloma cells and the
microenvironment as well, resulting in tumors being released from various tissues into
the blood away from their protective microenvironment niche, ultimately rendering them
vulnerable [33]. Additionally, the overall homing of myeloma cells has been shown to be
dependent on BTK [3,42]. This is significant because the adhesion of myeloma plasma cells
to the BM stroma modulates refractoriness and is a trigger for epithelial to mesenchymal
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transition (EMT). CXCR4 has been shown to regulate this EMT change in MM as well as
homing to the BM, indicating several methods in which BTK inhibition can sensitize MM
cells by disrupting the interaction of plasma cells with the BM stroma [6].
BTK is highly expressed in the MM stem cell as compared to the bulk of MM cells.
Overexpression of BTK in low expression cell lines increased stemness characteristics of
cells such as clonogenicity, self-renewal and drug resistance. In particular, the AKT/Wnt/β
catenin pathway dependent upregulation of key stemness genes NANOG, OCT4, SOX2
and MYC have been observed in myeloma cells overexpressing BTK (Figure 3). On the same
note, inhibition of BTK in high expressing MM cell lines reduced these same characteristics
and stemness gene expression [43,44].
BTK inhibition appears as a viable treatment option in the case of drug resistance,
as BTK has been shown to be expressed and activated in certain drug resistant cells
i.e., MM.1R, but not in parental non-resistant MM.1S cells, suggesting a shift in survival
pathways [39]. Mechanistic studies have outlined that BTK activates the AKT pathway,
leading to increases in drug resistance genes such as ABCB1 and BCL-2 and inhibition of
GSK3β and in turn leading to activation of Wnt/β catenin pathways (see Figure 3), leading
to drug resistance [43].
5. Development of BTK Inhibitors
Numerous BTK inhibitors have been developed over the past decade and a half,
some of which have been FDA approved for the treatment of various B-cell malignancies
(Figure 2) [45]. To date, no targeted kinase inhibitors have been approved for use in MM,
despite effective results in other related conditions [46]. BTK inhibitors that have been
approved by the FDA for other conditions include ibrutinib (PCI-32765) and acalabrutinib
(ACP-196), both of which bind BTK irreversibly by forming a covalent bond to a cysteine
residue at position 481 (C481) (Figure 4). The BTK-ibrutinib crystal structure had revealed
residues playing important roles in the protein-drug interaction [47]. The SH moiety of
C481, which is positioned close to the ATP pocket, forms covalent interactions with the
head region of ibrutinib and allows the adenine ring atoms to form multiple hydrogen
bonds with the backbone carbonyl of Glu475 and backbone amine of Met477 at the hinge
region. These interactions thus orientate the diphenyl ether moiety to surround itself with
conserved hydrophobic residues Leu542, Val416 and Met449 and charged residues like
Lys430, Asp539 and Ser538 behind Thr474, which acts as a gatekeeper (Figure 4).
Ibrutinib was the first developed BTK inhibitor and had been shown to have a large
amount of off target activity, associated side effects and resistance due to mutation at the
nucleotide binding pocket, thereby affecting the binding of inhibitors of this class [7,48–50].
Due to these issues, researchers have since taken unique approaches to develop a diversity
of inhibitors that are even more selective and that reversibly bind to the SH3 pocket of the
enzyme [51–53].
Currently, there are close to 20 BTK inhibitors undergoing different phases of clinical
trials for numerous B-cell related malignancies. These different drugs include compounds
which, depending on their structure, can selectively bind BTK irreversibly at either the C481
or Y223 position or reversibly bind at the C481 position. Said C481 position binding may
improve binding selectivity and efficacy of these second-generation inhibitors (Figure 5).
Some notable inhibitors currently in or recruiting for clinical trials for B-cell malignancies in
addition to ibrutinib (PCI-32765) and acalabrutinib (ACP-196) which are both undergoing
phase 1–3 trials include zanubrutinib (BGB-3111) a highly selective inhibitor which binds
irreversibly at C481 and is undergoing phase 1–3 trials, vecabrutinib (SNS-062) which
binds both highly selectively and reversibly at C481 as well as tirabutinib (ONO/GS-4059)
which binds irreversibly at the Y223 position. Some BTK inhibitors are undergoing trials
for autoimmune diseases as well, which may hold promise [7,49,54–56].
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Figure 4
Figure 4. BTK’s interaction with ibrutinib. The crystal structure of BTK bound with inhibitor ibrutinib showing the
interaction with protein (PDB: 5P9J). Protein colored in magenta, side chain in cyan and Ibrutinib in blue, ball and stick.
Side effects of BTK inhibitors are still being discovered but some major ones appear
to be cardiac related. This is not surprising considering the role that BTK plays in B-
cell development, but information about it remains insufficient. Atrial fibrillation seems
to be the primary cause for concern regarding BTK inhibitor side effects. Additionally,
interactions between BTK inhibitors and both anticoagulants and antiarrhythmic agents
have appeared [57]. Increased risk of infection, neutropenia, hypertension, hair and nail
changes, rash, diarrhea, and fatigue have all been reported to occur at least semi-frequently
and should be considered with monotherapy of BTK inhibitors. Cataracts have been
observed in animal studies and issues with bleeding and bruising have been described
in studies combining BTK Inhibitors with anticoagulant/anti-platelets [58,59]. These side
effects should be considered in study designs to reduce potential harm to at risk patients
with co-morbidity.
There are still many exciting BTK inhibitors in the drug development pipeline. These
drugs in preclinical development include most notably compounds such as RN-486, CGI-
1746, CNX-774 and LFM-A13 (Figure 6). Compound RN-486 is a small, potent, reversible
BTK inhibiting molecule with demonstrated highly specific sub-nanomolar activity. It is
mainly being examined in preclinical trials for autoimmune conditions such as rheumatism
and lupus [60,61]. CGI-1746 is a unique, extremely selective, ATP-competitive, small
molecule inhibitor of BTK. This molecule remarkably binds in a way to fill the SH3 binding
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pocket within the inactivated BTK molecule, thereby stabilizing it. It inhibits both auto-
and trans-phosphorylation of BTK but has yet to progress past preclinical trials in mice [61].
CNX-774 is an irreversible, small molecule BTK inhibitor that is orally bio-available. It is
extremely selective for BTK, as it forms a ligand directed covalent bond within the ATP
binding site at the Cys-481 position. CNX-774 is undergoing advanced preclinical trials [61].
LFM-A13 is another unique BTK inhibitor considered to be a first in class molecule due to
its dual BTK/Polo-like kinase inhibition. It is noted as having extremely promising effects
in multiple cancer cells, including lymphoma and leukemia. In mice, LFM-A13 has had
similar effects on myeloma cell growth, homing to bones and resorption, and the same is
true of other BTK inhibitors such as ibrutinib [61].
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Despite its efficacy, many patients have had to discontinue ibrutinib due to resistance
and subsequent disease progression. Some ibrutinib resistant patients have been shown to
have a C481S point mutation in BTK, as ibrutinib irreversibly binds to the C481 residue
(Figure 4), leading to the drug only reversibly inhibiting the mutated protein [62]. The
predominant strategy of covalently blocking C481 in inhibitor design and the subsequent
emergence of drug resistance due to C481S mutants’ clonal selection highlight the impor-
tance of adopting diverse strategies of binding as well as reversible and irreversible binding
mechanisms to further develop BTK inhibitors. Furthermore, the ability to bind and inhibit
BTK at different sites may also confer an advantage for avoiding mutati n .
Gain-of-fu ction muta ions have been identified as well in the treatment of CLL usi g
ibrutin b, ca sing BCR signaling to co tinue functioning normally despite BTK inhibition,
thus highlighting the important role that BCR signaling inhibition has on the effect of
BTK inhibition [63]. However, since the C481S mutation had been identified, in patients’
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refractory to ibrutinib, other BTK kinase domain mutations have been identified including
C481F/Y/R, T474I/S and L528W. Additionally, in CLL patients, mutations in BTK’s SH2
domain occurs at a frequency of 75% as well. Unlike mutations in kinase domain that
impair ibrutinib binding, SH2 domain T316A is far away from the ibrutinib binding site,
yet still confers resistance to a similar extent as C481S [64]. The significance and role of
these other mutations in the kinase domain and SH2 domain are still under investigation.
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6. How Good a Target Is BTK for Myeloma Therapy?
Targeting the BTK pathway stands as another novel means of treating and further
extending the lifespan of patients battling MM. BTK inhibition has a particularly impor-
tant treatment potential because of its multifaceted effect. Inhibiting this one pathway
can disrupt several aspects of the vicious cycle in which MM cancer cells and the BMM
interact. BTK inhibition has five primary effects in myeloma therapy. First and foremost,
BTK inhibition directly inhibits MM tumor growth. Second, it inhibits osteoclastic bone
resorption, thereby increasing tumor cytotoxic potential. Next, it inhibits the release of
osteoclast-derived tumor growth factors, further reducing tumor growth ability. Fourth,
BTK inhibition prevents the release of BM stromal cell derived growth factors, thereby
mitigating MM cell adhesion to the BM stromal cells [65]. Lastly, BTK inhibition impairs
MM stemness, as BTK knockdown reduces several key MM stem cell characteristics such
as side population cells, clonogenicity, induced pluripotent/embryonic stem cell genes
and drug resistance [44]. Therefore, BTK is unique, as it has been said to attack “the seed
and soil” [39]. Although it has potent effects on MM tumor and stem cells directly (the
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seed), what makes this agent so powerful is the effect it has on the supportive BMM niche
(the soil).
There have been several clinical trials completed using BTK inhibition in MM as either
a monotherapy or part of a combination therapy. Below is a brief outline of the different
clinical trials completed and key points that can be taken from them.
BTK inhibitors used in combination drug therapies have seen very promising results
in patients with R/R MM. Ibrutinib has been shown in patients with R/R MM to be very
effective in combination with low dose dexamethasone. In the clinical trial NCT01478581,
patients with R/R MM who have previously received at least two lines of therapy with one
of which being an immunomodulator, were given escalating dosages of ibrutinib daily with
or without 40 mg of dexamethasone weekly in a Simon Stage 2 study design. Despite being
a heavily treated population with patients having received a median of 4 prior treatments,
ibrutinib with dexamethasone still produced encouraging responses [46]. The primary
outcome of clinical benefit response (CBR) showed that 420 mg/day of ibrutinib alone had
a 7.7% CBR with a duration of 27.6 months. Additionally, a higher dosage of 840 mg/day
of ibrutinib with 40 mg of dexamethasone per week had a 27.9% CBR with an average
duration of 11.5 months. All patients completed the trial, highlighting the notable safety
profile of ibrutinib and likely other BTK inhibitors.
In phase 2 clinical trial NCT02943473, ibrutinib was also examined in patients with
high-risk smoldering (HRS) MM. The patients received 560 mg of ibrutinib daily and
primary outcome showed that 71.4% of patients remained free of MM for at least 1 year.
However, the trial was terminated and none of the secondary outcomes had data reported.
A total of 50% of patients with HRS MM are expected develop MM 2 years after diagnosis.
A better controlled study with larger sample sizes and higher dosages of ibrutinib may
yield more encouraging results.
The BTK inhibitor acalabrutinib was recently examined with and without dexametha-
sone in a phase 1b study of patients with MM. In one arm, patients received 100 mg of
acalabrutinib twice per day and showed a minor response (MR) frequency of 7.7%, a stable
disease (SD) frequency of 38.5%, a progressive disease (PD) frequency of 30.8% and a not
evaluable (NE) frequency of 23.1%. In the other arm, patients received 100 mg twice per
day with 40 mg dexamethasone once weekly and showed a MR frequency of 14.3%, SD
frequency of 42.9%, a PD frequency of 7.1% and a NE frequency of 35.7%. These results led
to the study being terminated due to lack of efficacy. However, valuable insights regarding
the safety profile and pharmacokinetics of this BTK inhibitor were obtained.
BTK inhibition and bortezomib as a combination therapy has also shown promising
results, as both isolate the NF-κB pathway in different yet synergistic ways. Additionally,
BTK therapy has been shown to sensitize bortezomib resistant MM cells to bortezomib [66].
Clinical trial NCT02902965 examined this combination using ibrutinib with the addition of
dexamethasone in a phase 2 study treating R/R MM patients who had received 1–3 prior
lines of therapy and had demonstrated progressive disease since last treatment. However,
the study was suspended following increased incidence of infections. Incidence of adverse
events were however largely consistent with previous reports across hematologic malig-
nancies and the study was restarted. Nevertheless, 57% of patients had clinical responses
with a median response duration of 9.5 months. The study was ultimately terminated due
to an inability to achieve the primary endpoint [67].
Clinical trial NCT01962792 examined BTK inhibition in combination with carfilzomib
with and without dexamethasone in R/R MM patients via a phase 1/2b study. All patients
completed the dose escalation and DLT observation portion of this study. Patients received
a median of 3 prior therapies, including 70% that received autologous stem cell transplants.
The phase 2b portion used either 560 mg or 840 mg of daily Ibrutinib with IV carfilzomib
and dexamethasone. A total of 30% of patients discontinued treatment due to toxicity. The
study indicated promising results, despite most patients having advanced MM and a large
subset being refractory to bortezomib and an IMiD. The study yielded an ORR of 67%,
CBR of 76% and median PFS of 7.2 months. Remarkably, patients that were refractory to
Int. J. Mol. Sci. 2021, 22, 5707 14 of 18
bortezomib showed particularly robust responses, with an ORR of 71% and median DOR
of 9.1 months [68].
The clinical trial NCT02548962 used ibrutinib with pomalidomide and dexamethasone
in R/R MM patients. The trial was terminated by the sponsor after completing phase 1.
Ibrutinib was given in either 420 mg or 840 mg in a combination with 4 mg of pomalido-
mide and 40 mg of dexamethasone. The group that received 420 mg of ibrutinib with
pomalidomide and dexamethasone showed a 50% CBR frequency and average 6.5 -month
DOR. The group that received 840 mg of ibrutinib in the combination had a 66.7% CBR
frequency and 7.3-month DOR.
Despite all the advances in treatment modalities, MM remains incurable. For this
reason, there is a need to continue researching and expanding options for long term disease
treatment and relapse control in MM patients. No matter how effective the treatment,
MM relapses begin occurring more frequently after each remission. Therefore, targeting
the myeloma stem cell appears to be a must. BTK has been shown to be one of the most
promising kinase inhibitor options currently in development for MM. This is due to BTK’s
robust expression in MM cells and its effect on both the tumor, stem cells and BMM [43,69].
BTK inhibition does not appear to be as cytotoxic to tumor cells as other treatments such as
proteasome inhibitors or immunomodulators; however, the effect of targeting the MM stem
cells and BM microenvironment may prove it to be an even more valuable and effective
treatment in the long term and in relapsed/refractory (R/R) patients. This may prove to be
especially important because the current treatments available still fail to prevent patients
from relapse [70].
7. Future Directions
BTK inhibition has shown remarkable activity across B-cell histologies and has promise
to be used as a single drug therapy for MM patients in certain circumstances due to its
efficacy and lack of toxicity [39,65,71]. BTK inhibitors appear to be most valuable in
isolation therapy for cases of drug resistant MM, as the BTK pathway appears to be
selectively upregulated in these phenotypes [72], and in preventing relapse or disease
progression.
Combination therapies including BTK inhibitors have strong evidence of efficacy
via the several clinical trials completed. Combination with immune therapies such as
monoclonal antibodies have become an area of interest for researchers as well. Given
BTK inhibitors’ method of interaction with the bone marrow and stem cells, combination
therapies appear to be an extremely promising direction for future research [45,66].
8. Conclusions
BTK inhibitors appear to be an exciting and viable new approach within the expand-
ing arsenal of drugs used to treat MM. A diverse set of irreversible and reversible BTK
inhibitors varying in shape, size and chemical scaffolds have been developed over the
years. Structural details of these inhibitor complexes reveal conformational plasticity of
the BTK nucleotide binding pocket, which could be exploited further to explore a rich set
of pharmacophores for structure-based design of inhibitors relevant to MM phenotypes.
In the kinase pocket, structural flexibility of the helix C, Gly-rich loop, DFG sequence
and activation loop offer diverse approaches to design novel drug leads based on the
physiological relevance of these states (Figure 5). Our analysis of diverse ensembles of
BTK-inhibitor structures show conserved active site waters whose spatial disposition can
also be utilized to design/add novel scaffolds to mimic interactions of displaced water
oxygens (Figure 6).
Inhibiting the BTK mediated pathways offers a variety of benefits against both MM
cancer cells themselves and the tumor microenvironment niche, which support the can-
cers by promoting growth and resistance to treatment. Additionally, the effect that BTK
inhibition has on myeloma cell homing and adhesion to the bone marrow can inhibit
important functions in MM survival, reducing cytokine secretion and sensitizing drug
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resistant cells to chemotherapy [73]. With all factors considered, BTK inhibition in MM
has an irreplaceable three-pronged effect, attacking the cancerous plasma cell itself, its
stem cells and the BMM, presenting it as one of the most exciting and robust currently
developing MM targeted therapies.
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